A systematic review and economic model of the effectiveness and ...

Clinical effectiveness
TABLE 9 MPH medium dose (15–30 mg/day) plus non-drug intervention versus placebo
Study Design Intervention – N Age Duration Core outcomes
(years) (weeks)
Administered two or more times daily
Brown, 1986 42 P MPH (20.08 mg/day, b.d.) – 40 5.7–13.1 3 months Core: CPRS: Hyperactivity Index; ACTeRs: hyperactivity
QoL: not reported
AE: not reported.
Pelham, 1993 79 C (3×) MPH (16.2 mg/day, b.d.) – 31 5.4–9.9 6 Core: no hyp; IOWA CTRS: inattention/overactivity
QoL: not reported
AE: not reported
Kolko, 1999 69 C (4×) MPH (0.60 mg/kg/day, b.d.) – 22 7–13 6 Core: no hyp; IOWA CTRS: inattention/overactivity
QoL: not reported
AE: SSERS
ACTeRS, ADD-H Comprehensive Teachers’ Rating Scale; C, crossover trial (number of crossovers); CPRS, Conners’ Parent Rating Scale; CTRS, Conners’ Teacher Rating Scale; P,
parallel trial; SSERS, Stimulant Drug Side Effects Rating Scale.
36 TABLE 10
Results for hyperactivity [MPH medium dose (15–30 mg/day) plus non-drug intervention versus placebo]
Study Scale MPH medium dose + non-drug: mean (SD) Placebo: mean (SD) Mean difference
5–13 years
Brown, 1986 42 MD (95% CI)
CPRS (Hyperactivity Index) 13.78 (8.14) 17.25 (7.50) –0.31 (–4.47 to 3.85)
ACTeRs (hyperactivity) 19.60 (2.63) 17.50 (4.41) 0.68 (–1.89 to 3.25)
Lower scores represent a better behavioural outcome.
ACTeRS, ADD-H Comprehensive Teachers’ Rating Scale; CPRS, Conners’ Parent Rating Scale.